| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $4,976,081 | 27 | 100 |
| Scadden David | director | 0 | $0 | 1 | $8,768 | $-8,768 |
| Viswanadhan Krishnan | Chief Corp Dev & Strategy | 0 | $0 | 2 | $184,967 | $-184,967 |
| Washburn Theodore James Jr. | Principal Accounting Officer | 0 | $0 | 2 | $216,633 | $-216,633 |
| Jones Cecilia | Chief Financial Officer | 0 | $0 | 3 | $334,266 | $-334,266 |
| Burns James William | Chief Legal Officer | 0 | $0 | 3 | $344,390 | $-344,390 |
| Milanova Tsveta | Chief Commercial Officer | 0 | $0 | 4 | $353,311 | $-353,311 |
| Goff Brian | Chief Executive Officer | 0 | $0 | 3 | $1.69M | $-1.69M |
| Gheuens Sarah | Chief Medical Officer | 0 | $0 | 9 | $1.84M | $-1.84M |
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established …
Over the last 12 months, insiders at Agios Pharmaceuticals, Inc. have bought $0 and sold $4.98M worth of Agios Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Agios Pharmaceuticals, Inc. have bought $0 and sold $4.99M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 40,322 shares for transaction amount of $1.25M was made by FOUSE JACQUALYN A (Chief Executive Officer) on 2019‑11‑13.
| 2026-10-26 | Sale | Gheuens Sarah | Chief Medical Officer | 7,866 0.0135% | $37.69 | $296,470 | -7.15% | |
| 2026-10-22 | Sale | Gheuens Sarah | Chief Medical Officer | 500 0.0008% | $37.52 | $18,760 | -0.71% | |
| 2026-10-21 | Sale | Gheuens Sarah | Chief Medical Officer | 1,489 0.0025% | $37.53 | $55,882 | -0.48% | |
| 2026-08-04 | Sale | Gheuens Sarah | Chief Medical Officer | 30,000 0.0485% | $30.48 | $914,400 | +5.41% | |
| 2026-07-01 | Sale | Gheuens Sarah | Chief Medical Officer | 4,007 0.0068% | $37.56 | $150,503 | -9.30% | |
| 2026-04-02 | Sale | Goff Brian | Chief Executive Officer | 19,068 0.033% | $34.71 | $661,850 | -6.01% | |
| 2026-04-02 | Sale | Gheuens Sarah | Chief Medical Officer | 2,940 0.0051% | $34.71 | $102,047 | -6.01% | |
| 2026-04-02 | Sale | Jones Cecilia | Chief Financial Officer | 3,141 0.0054% | $34.71 | $109,024 | -6.01% | |
| 2026-04-02 | Sale | Burns James William | Chief Legal Officer | 3,280 0.0057% | $34.71 | $113,849 | -6.01% | |
| 2026-04-02 | Sale | Milanova Tsveta | Chief Commercial Officer | 3,262 0.0057% | $34.71 | $113,224 | -6.01% | |
| 2026-04-02 | Sale | Viswanadhan Krishnan | Chief Corp Dev & Strategy | 2,959 0.0051% | $34.71 | $102,707 | -6.01% | |
| 2026-03-05 | Sale | Viswanadhan Krishnan | Chief Corp Dev & Strategy | 2,959 0.0051% | $27.80 | $82,260 | +18.42% | |
| 2026-03-03 | Sale | Washburn Theodore James Jr. | Principal Accounting Officer | 5,272 0.0089% | $28.88 | $152,255 | +14.89% | |
| 2026-03-02 | Sale | Goff Brian | Chief Executive Officer | 18,055 0.0295% | $28.96 | $522,873 | +11.95% | |
| 2026-03-02 | Sale | Gheuens Sarah | Chief Medical Officer | 4,055 0.0066% | $28.96 | $117,433 | +11.95% | |
| 2026-03-02 | Sale | Jones Cecilia | Chief Financial Officer | 5,035 0.0082% | $28.96 | $145,814 | +11.95% | |
| 2026-03-02 | Sale | Milanova Tsveta | Chief Commercial Officer | 2,868 0.0047% | $28.96 | $83,057 | +11.95% | |
| 2026-03-02 | Sale | Burns James William | Chief Legal Officer | 5,218 0.0085% | $28.96 | $151,113 | +11.95% | |
| 2026-03-02 | Sale | Washburn Theodore James Jr. | Principal Accounting Officer | 2,223 0.0036% | $28.96 | $64,378 | +11.95% | |
| 2026-01-05 | Sale | Milanova Tsveta | Chief Commercial Officer | 2,872 0.0048% | $27.02 | $77,601 | +13.66% |
| Scadden David | director | 17603 0.0295% | $549,213.60 | 1 | 6 | <0.0001% |
| Celgene European Investment Co LLC | 10 percent owner | 1856353 3.1094% | $57.92M | 4 | 0 | +32.26% |
| CELGENE CORP /DE/ | 10 percent owner | 1777824 2.9778% | $55.47M | 2 | 0 | +14.63% |
| FOUSE JACQUALYN A | director | 149220 0.2499% | $4.66M | 1 | 5 | +28.93% |
| Schenkein David P | director | 122854 0.2058% | $3.83M | 1 | 58 | +28.93% |
| Tessier-Lavigne Marc | director | 101009 0.1692% | $3.15M | 1 | 0 | <0.0001% |
| MARAGANORE JOHN | director | 36209 0.0606% | $1.13M | 4 | 2 | +52.79% |
$8,217,280 | 112 | 46.33% | $1.6B | |
$607,395,062 | 99 | 4.23% | $1.88B | |
$47,419,530 | 58 | 17.20% | $1.96B | |
$1,376,668 | 53 | 18.46% | $2.1B | |
$61,893,001 | 38 | 19.63% | $1.89B |
| Increased Positions | 149 | +58.43% | 20M | +31.56% |
| Decreased Positions | 116 | -45.49% | 22M | -34.24% |
| New Positions | 68 | New | 8M | New |
| Sold Out Positions | 46 | Sold Out | 15M | Sold Out |
| Total Postitions | 288 | +12.94% | 62M | -2.68% |
| Farallon Capital Management Llc | $157,129.00 | 9.97% | 5.78M | +13,600 | +0.24% | 2025-09-30 |
| Vanguard Group Inc | $152,341.00 | 9.66% | 5.6M | -77,143 | -1.36% | 2025-09-30 |
| Blackrock, Inc. | $123,553.00 | 7.84% | 4.55M | -288,022 | -5.96% | 2025-09-30 |
| Bellevue Group Ag | $100,967.00 | 6.41% | 3.71M | +124,586 | +3.47% | 2025-09-30 |
| Erste Asset Management Gmbh | $75,150.00 | 4.77% | 2.76M | +438,411 | +18.84% | 2025-09-30 |
| Paradigm Biocapital Advisors Lp | $72,667.00 | 4.61% | 2.67M | +2M | +134.01% | 2025-09-30 |
| Wellington Management Group Llp | $67,173.00 | 4.26% | 2.47M | +2M | +485.46% | 2025-09-30 |
| Commodore Capital Lp | $63,555.00 | 4.03% | 2.34M | +13,287 | +0.57% | 2025-09-30 |
| State Street Corp | $61,501.00 | 3.9% | 2.26M | +311,599 | +15.97% | 2025-09-30 |
| Macquarie Group Ltd | $53,221.00 | 3.38% | 1.96M | +57,505 | +3.03% | 2025-09-30 |